Ranbaxy Laboratories Ltd.

Leading Practices

• Through collaborations, Ranbaxy is the only generics company covered by Index 2010 that conducts innovative R&D for dengue and tuberculosis.
• The company commits to making its best efforts to control the pricing practices of local sales agents and prevent 'profiteering'.

Changes Compared to Index 2008

• Since the publication of Access to Medicine Index 2008, Ranbaxy has commenced Phase III clinical studies for its anti-malarial FDC in India, Bangladesh and Thailand.
• In 2008, Ranbaxy began collaboration with the Department of Biotechnology of the Indian Ministry of Science and Technology, to explore its compound library with the aim of identifying new chemical entities (NCEs) for tuberculosis.
• Ranbaxy is one of the generics suppliers involved in the HIV/AIDS equitable pricing scheme of the Clinton Health Access Initiative.

Suggested Areas for Improvement

• Ranbaxy's ATM management system lacks quantitative and qualitative target setting and comprehensive and systematic reporting of ATM activities.
• Unlike some of its sector peers such as Cipla, the company has not been found to engage in capacity building initiatives with local Index Country institutions and/or manufacturers in the areas of research, quality management and distribution.
• Ranbaxy lacks public disclosure across all technical areas, particularly its public policy positions on important ATM issues, marketing activities in the Index Countries and specific resources (human, financial and technical) dedicated to ATM activities.